Acute Lymphoblastic Leukemia(B-ALL)

At Lu Daopei Hospital, a world leader in the treatment of blood cancers, a 61-year-old patient from Syria battling acute lymphoblastic leukemia (ALL) found a new chance at life through CAR-T therapy, in partnership with BIOOCUS, which provided the CAR-T product used in her treatment.

Mohammed, the patient’s son, shared his mother's long journey with leukemia. Diagnosed with ALL in 2012, his mother initially responded to chemotherapy and went into remission for five years. Unfortunately, her disease relapsed in 2018, leading to another round of chemotherapy and an allogeneic bone marrow transplant. However, six months post-transplant, the leukemia returned again, and further chemotherapy was no longer an option. The family searched for alternative treatments but faced limitations in Syria, where advanced therapies like CAR-T were unavailable.

After extensive research, Mohammed discovered that China was at the forefront of CAR-T therapy and that Lu Daopei Hospital had treated over 500 patients with high success rates, particularly for ALL, boasting remission rates above 90%. Encouraged by these statistics, Mohammed arranged for his mother to receive treatment at Lu Daopei Hospital.

Upon arrival in China, doctors discovered that the patient had an extremely high tumor burden of 80% in her bone marrow, classifying her as a high-risk patient. Despite these challenges, the medical team at Lu Daopei Hospital, including Dr. Peggy Lu and Dr. Song, initiated treatment using CAR-T cells provided by BIOOCUS, which specializes in delivering cutting-edge CAR-T products to hospitals worldwide.

After just 15 days of CAR-T therapy, combined with chemotherapy conditioning, the patient achieved complete remission. Her test results showed MRD-negative, meaning no detectable leukemia cells remained. Mohammed expressed deep gratitude for the outcome, remarking, "It's a miracle. Chemotherapy or any other immunotherapy wouldn't have delivered the same result. The CAR-T treatment saved my mother’s life."

He also praised the team at Lu Daopei Hospital, stating, "The doctors and staff, particularly those at the International Center, were incredibly skilled and attentive. They provided not only top-tier medical care but also emotional support throughout this challenging journey."

This case exemplifies the power of CAR-T therapy in treating high-risk ALL patients, especially those for whom traditional treatments have failed. With BIOOCUS as a trusted partner in providing state-of-the-art CAR-T products, Lu Daopei Hospital continues to lead in delivering life-saving therapies and advancing cancer treatment.

For patients battling ALL, CAR-T therapy offers new hope, even in the most challenging cases. Lu Daopei Hospital remains committed to providing innovative treatments and improving the outcomes for patients with blood cancers.